Current Report Filing (8-k)
2016年6月7日 - 3:41AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 3, 2016
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
1880
Century Park East, Suite 1000
|
|
Los
Angeles, California
|
90067
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On
June 3, 2016, the stockholders of Ritter Pharmaceuticals, Inc. (the “Company”) approved an amendment to the Company’s
2015 Equity Incentive Plan (the “Plan”) at the 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”).
The amendment to the Plan (the “Amendment”), had been previously approved by the Board of Directors (the “Board”)
of the Company on January 26, 2016, subject to stockholder approval. The Amendment provides for the following changes to the Plan,
among others: (a) an increase in the number of shares that may be issued pursuant to awards under the Plan by 475,000 shares to
an aggregate of (i) 803,289 shares plus (ii) any shares which are available for grant under the 2008 Stock Plan and the 2009 Stock
Plan (the “Prior Plans”) on the effective date of the Plan or were or are subject to awards under the Prior Plans
which, after the effective date of the Plan, were or are forfeited or lapse unexercised or were or are settled in cash and are
not issued under the Prior Plans; (b) an increase in the number of shares that may be issued under the Plan pursuant to incentive
stock options intended to qualify under Section 422 of the Internal Revenue Code by 475,000 shares to an aggregate of 803,289
shares; and (c) an increase in the maximum aggregate number of shares with respect to one or more stock awards that may be granted
to any one person during a calendar year from 65,657 shares to 300,000 shares.
The
material terms of the Amendment are described on pages 36 and 37 of the Company’s definitive proxy statement (the “Proxy
Statement”) for the 2016 Annual Meeting filed with the Securities and Exchange Commission on April 21, 2016 under the heading
“Proposal 3—Approval of Amendment to the 2015 Equity Incentive Plan,” which description is incorporated herein
by reference. The description of the Amendment included in the Proxy Statement is qualified in its entirety by reference to the
full text of the Amendment, which is attached hereto as Exhibit 10.1, and the terms of which are incorporated by reference into
this Item 5.02.
Item
5.07. Submission of Matters to a Vote of Security Holders.
The
final voting results of the matters voted on at the 2016 Annual Meeting are provided below.
Proposal
1—Election of Directors
Each
of the nominees for election to the Board was elected to hold office for a one-year term and until their respective successors
are elected and qualified by the following votes:
Name
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Noah Doyle
|
|
|
5,390,013
|
|
|
|
6,997
|
|
|
|
993,533
|
|
Matthew W. Foehr
|
|
|
5,331,883
|
|
|
|
65,127
|
|
|
|
993,533
|
|
Paul V. Maier
|
|
|
5,331,983
|
|
|
|
65,027
|
|
|
|
993,533
|
|
Gerald T. Proehl
|
|
|
5,329,883
|
|
|
|
67,127
|
|
|
|
993,533
|
|
Andrew J. Ritter
|
|
|
5,393,513
|
|
|
|
3,497
|
|
|
|
993,533
|
|
Ira E. Ritter
|
|
|
5,391,413
|
|
|
|
5,597
|
|
|
|
993,533
|
|
Michael D. Step
|
|
|
5,393,613
|
|
|
|
3,397
|
|
|
|
993,533
|
|
Proposal
2—Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
The
ratification of the appointment by the Audit Committee of the Board of Mayer Hoffman McCann P.C. as the independent registered
public accounting firm of the Company for the fiscal year ending December 31, 2016 was approved by the following vote:
For:
|
|
|
6,379,244
|
|
Against:
|
|
|
9,269
|
|
Abstained:
|
|
|
2,030
|
|
Broker Non-Votes:
|
|
|
—
|
|
Proposal
3—Approval of Amendment to the 2015 Equity Incentive Plan
The
Amendment was approved by the following vote:
For:
|
|
|
5,285,385
|
|
Against:
|
|
|
90,583
|
|
Abstained:
|
|
|
21,042
|
|
Broker Non-Votes:
|
|
|
993,533
|
|
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
10.1
|
|
Amendment
to 2015 Equity Incentive Plan
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
RITTER
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
|
|
Name:
|
Michael D. Step
|
|
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
|
Date:
|
June
6, 2016
|
|
|
|
Exhibit
Index
Exhibit
No.
|
|
Description
|
|
|
|
10.1
|
|
Amendment
to 2015 Equity Incentive Plan
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 9 2024 まで 10 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about Ritter Pharmaceuticals Inc (ナスダック市場): 0 recent articles
その他のRitter Pharmaceuticals Incニュース記事